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Dose emission from a Turbohaler1 has been shown to be dependent on the rate of inhalation, with an optimal flow
of 60 lmin71 recommended. Some patients may need counselling to achieve this fast inhalation. Inhalation rate
profiles of 24 asthmatics were measured when they inhaled through a placebo Turbohaler1. The setting was a
community pharmacy when the asthmatics came to collect their next supply of medication. Profiles were measured
before and after counselling on how to use the Turbohaler. The mean (SD) peak inhalation rate through the
Turbohaler pre- and post-counselling was 480 (168) and 547 (176) lmin71, and their inspiratory volume was 175
(068) and 194 (062) l, respectively. Their mean (SD) percent predicted FEV1 was 570 (189)%. After counselling,
12 patients achieved an inhalation rate of460 lmin71 and a further four obtained455 lmin71. Emphasis should
be placed on counselling patients prescribed all types of inhaled devices rather than concentrating on metered dose
inhalers.
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It has been shown that there is a dierence in the resistance
between the types of dry powder inhaler devices which are
available (1). Some have a low, others have a medium and
the remainder have a high, resistance to inspiration. If the
resistance is high, then a greater inspiratory eort is
required to generate the same inhalation rate as that with
a lower resistance.
In vitro studies have highlighted that the emitted dose
from a Turbohaler is dependent on the inspiratory flow
(2,3). Similar results have been shown by in vivo studies
using gamma scintigraphy to visualize lung deposition (4,5).
In nine asthmatics Newman et al. (4) reported that more
terbutaline was delivered to the lungs when they inhaled
through the Turbohaler at 60 lmin71 compared with
30 lmin71; also, the bronchodilatory eect was greater at
the higher rate (4). Borgstro¨m et al. highlighted that this
phenomena was device-specific (5). Using budesonide
inhaled from a Turbohaler by 10 healthy volunteers, they
showed that for an inhalation rate of 58 lmin71 the total
lung dose was 277% compared with 148% at 36 lmin71.Paper received 31 August 1999 and accepted in revised from 5
December 1999.
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0954-6111/00/050501+04 $35?00/0Studies have shown that most asthmatic children use the
Turbohaler with an inhalation rate of 30–60 lmin71 (6),
and that this rate is dependent on age (7). A study of 59
young asthmatics has shown that when using a Turbohaler
those with a higher forced inspiratory volume in 1 sec
achieved more bronchodilation (8). This highlights the
flow-dependent dose emission from this device which has
also been indicated by suggestion of 10 stable asthmatic
subjects using five dierent modes of inhalation (9). Peak
inhalation rates could not be accurately predicted from
spirometry (10).
The instructions for use leaflet supplied with a Turbo-
haler indicates that the inhalation should be as deep and
hard as possible. This highlights the need for an optimal
flow of 60 lmin71. However, because of the high resistance,
some patients may not be able to generate the required
inspiratory eort during inhalation. In an outpatient clinic,
using a Turbohaler Trainer, it has been reported that only
20% of asthmatics could achieve this rate or more (11). It
may be that the patients who could not inhale at this
required rate need counselling to use a deep and hard
inhalation as mentioned in the patient leaflet. Patients
picking up their inhaled medication from a community
pharmacy will be the last contact that they have with a
healthcare profession before inhaling their medication at
home. We have, therefore, measured inhalation rate profiles
before and after counselling when asthmatics inhale
through a Turbohaler in the setting of a community
pharmacy when they come to pick up their next supply of
medication.# 2000 HARCOURT PUBLISHERS LTD
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Local ethical approval was obtained and patients gave
signed written consent. Asthmatic patients (confirmed with
clinic notes) leaving a community pharmacy with their
inhaled medication were asked to participate as they left the
premises. Those that were asked to participate were selected
during the dispensing of their inhalers according to a
randomization procedure. Inhalation rate profiles when
patients inhaled through a placebo Turbohaler (Astra
Pharmaceuticals Ltd, UK) were recorded using a method
proposed by Clark and Hollingworth (1). Each inhalation
profile was measured via pressure drop readings from a
small probe sited in the inhalation channel of the
Turbohaler. External in vitro assessment showed that the
position of the probe did not aect the resistance or airflow
through the Turbohaler. Pressure drop readings were
electronically relayed every 01 sec into a spreadsheet to
record the inhalation flow rate. These were also converted
into cumulative inspired volume.
Prior to inhalation, each patient was given a copy of the
inhalation instructions provided with a Turbohaler. They
were not asked if they had been counselled or how to use a
Turbohaler. Patients were given 10min to read and
understand the information. One inhalation rate profile,TABLE 1. Individual data when patients inhaled with a Turbohal
Subject Age
(years)
FEV1
(l)
FEV1 %
predicted
1 45 231 89
2 24 263 68
3 51 161 62
4 49 121 42
5 40 231 80
6 46 112 49
7 13 217 56
8 56 101 32
9 46 168 49
10 47 098 24
11 10 210 78
12 45 231 89
13 69 079 40
14 76 210 60
15 68 203 72
16 74 121 47
17 64 074 32
18 72 162 57
19 74 163 54
20 61 108 35
21 74 109 61
22 75 122 47
23 58 194 88
24 74 123 62through the Turbohaler, was measured using the patient’s
normal inhalation technique. Patients were then counselled
on the inhalation technique to be used with a Turbohaler,
including instructions to incorporate a deep and fast
comfortable inhalation. One inhalation profile with the
Turbohaler was then measured. Spirometry was then
measured as the best of three forced manoeuvres.
Results
Table 1 shows that 24 asthmatic patients, prescribed a
Turbohaler, whose mean age (SD) was 559 (192) years,
ranging from 10 to 76 years, completed the study. Their
mean (SD) FEV1 was 159 (055) l which is 570 (189)% of
predicted with a range of 24 to 89%. Thirteen also used a
metered dose inhaler, four a rotahaler and two used a
diskhaler. Their mean (SD) inhalation rate profiles when
inhaling through the adapted placebo Turbohaler pre- and
post-counselling are shown in Fig. 1. Individual inhalation
data are shown in Table 1, with a summary in Table 2.
These tables show that statistically significant improve-
ments were obtained after counselling. Pre-counselling,
seven patients achieved an inhalation rate of 460 lmin71.
One of these patients inhaled at a flow rate of560 lmin71er pre- and post-inhalation technique counselling
Peak inspiration rate
(lmin71)
Inhaled volume
(l)
pre post pre post
472 424 144 190
654 581 160 129
522 602 223 232
597 599 144 194
440 430 145 173
124 131 072 090
307 573 193 254
451 588 224 230
543 687 091 196
547 832 363 320
718 731 143 164
626 687 177 244
187 156 091 100
599 659 276 297
715 711 267 255
281 555 095 108
443 507 155 183
573 607 242 270
228 409 151 201
595 677 177 189
277 272 141 133
621 656 214 222
579 645 179 188
427 411 120 107
FIG. 1 Mean (SD) inhalation rate profiles through a
Turbohaler before and after counselling.
THE INSPIRATORY MANOEUVRE WHEN ASTHMATICS INHALE THROUGH A TURBOHALER 503post-counselling. Five other patients almost achieved
60 lmin71 (>55 lmin71). Six further patients who did
not achieve an inhalation rate of 60 lmin71 before
counselling did so afterwards. Four other patients almost
achieved 60 lmin71 (>55 lmin71). The mean (SD) FEV1 %
of predicted, for the 12 patients who did and did not
achieve an inspiration rate of 60 lmin71 after counselling
were 603 (202) and 537 (194)%, respectively. The median
dierence (95% confidence interval) between these was
790 (7260, 100)%.
Conclusions
Only one inhalation was carried out pre- and post-
counselling, because attempts were made to mimic clinic
use. Nevertheless, it would be fair to indicate that their first
attempt represents their worst and some patients are
prescribed two doses. All patients were counselled to use
a comfortable inhalation. This is emphasized in Fig. 1, in
that the average inhalation time was 3 sec. Clark and
Hollingworth (1) have stressed this. They showed that using
a short sharp burst to measure a peak inspiration rate,
similar to that of a peak expiration rate, provides higher
values than a comfortable inhalation, but this is not theTABLE 2. Inhalation data when using the Turbohaler (n=24)
Mean (SD)
Pre-counselling Post-c
Peak inhalation rate (lmin71) 480 (168) 54
Inhaled volume (l) 175 (068) 19
Time to peak (sec) 054 (046) 04
*t-testmethod recommended for inhalation. Dewar et al. (11) have
reported that a higher percentage of their COPD patients
could generate an inhalation rate of 460 lmin71 through
the Turbohaler than these 24 asthmatics or the outpatients
studied by Johnson et al. (12). However, Dewar et al. (11)
indicate that the peak inspiration rates were measured by a
spirometer in reverse mode to which was attached a placebo
Turbohaler.
At present, emphasis is placed on training patients on
how to use their metered dose inhalers, and that counselling
inhalation techniques for dry powder inhalers is not
necessary because they are breath-activated. The significant
improvements obtained highlight the importance of coun-
selling patients on how to use all types of inhalers. This
applies more to those dry powder inhalers with a medium
to high resistance whose emitted dose is aected by the
inhalation rate. It is not so important for low resistance dry
powder inhalers whose emitted dose is not flow-dependent.
Most of the patients were in the moderate–severe
category, but they were stable and thus able to walk into
the community pharmacy to collect their prescription. The
inhalation rate profiles were therefore measured during a
period when their asthma was well controlled. The results,
therefore, probably represent the best they could achieve.
During exacerbations their inspiration eort will be
reduced, and thus their inhalation would be lower.
Studies have shown that patients do receive a proportion
of the dose at inhalation flows of 30 lmin71 (4,5). Although
this is not a consistent nominal dose (2,3), the patient’s dose
can be titrated according to their response, and reports
suggest that flow rates below 60 lmin71 can give eective
clinical control (4,9,13). However, variability of dose
emission is increased at lower flow (2,3) and, as indicated
above, any deterioration could reduce the patient’s
inspiratory capability, and thus the dose emitted would be
decreased at a time when they require large doses delivered
to their airways.
Fifty percent could achieve an inspiration rate greater
than 60 lmin71 which is higher than the 20% value
reported for hospital outpatients (12). A further four
almost managed this value. The dierence to the Johnson
et al. outpatients (12) may be that their patients were not as
stable and fit as the patients who walked into the
community pharmacy to take part in this study. The
majority were older than 30 years, whereas studies have
shown that for children the inhalation rate through theMean dierence
(95% confidence interval)
P*
ounselling
7 (176) 66 (241,1091) 00036
4 (062) 020 (006,036) 00058
3 (023) 011 (7005,027) N.S.
504 G. M. HAWKSWORTH ET AL.Turbohaler is age related (7,14). Nevertheless, only half the
patients could achieve the required rate even after counsel-
ling, and whether they would continue to use this inhalation
rate is not certain. The lack of a dierence in the spirometry
between those who could and could not inhale at a rate of
460 lmin71 with the Turbohaler suggests that it is not easy
to identify those who can achieve this inspiration rate. This
highlights the lack of a correlation reported between
spirometry and inspiratory values (10,15), and suggests
that focus should be directed towards measurements of
inspiratory eort (8). An In-Check Meter has recently been
introduced. This is a simple device which can measure a
patient’s inhalation rates during inhalation. We have
studies in progress to evaluate the use of this meter to
identify which inhaled product to prescribe for each patient.
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